Glenmark Pharmaceuticals Q2 Results
- BSE: 532296
- NSE: GLENMARK
- ISIN: INE935A01035
- Sector: Biotechnology & Drugs
BSE
2,199.20
20.65 (0.95%)
20.65 (0.95%)Volume12.47 K
Updated: Tue 9 Jun, 2026 | 11:36:37
NSE
2,202.5026.00 (1.19%)
26.00 (1.19%)Volume2.51 L
Updated: Tue 9 Jun, 2026 | 11:23:25
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
Quarter ended Sep 25
Note: Comparison is on QoQ basis
Quarterly - Glenmark Pharmaceuticals Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 25 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 5,213.64 | 3,137.08 | 66.19% | 2,952.16 | 76.60% |
| Depreciation/ Amortization | 141.20 | 129.93 | 8.68% | 120.28 | 17.39% |
| Operating Income | 833.24 | 127.36 | 554.23% | 481.63 | 73.00% |
| Net Income | 610.35 | 46.87 | 1202.20% | 354.21 | 72.31% |
| Other Operating Expenses Total | 1,336.55 | 905.59 | 47.59% | 975.24 | 37.05% |
| Net Income Before Taxes | 967.40 | 95.58 | 912.16% | 472.57 | 104.71% |
| Total Revenue | 6,046.87 | 3,264.44 | 85.23% | 3,433.80 | 76.10% |
| Selling/ General/ Admin Expenses Total | 1,086.26 | 762.75 | 42.41% | 786.56 | 38.10% |
| Diluted Normalized EPS | 52.58 | 7.29 | 621.64% | 12.55 | 318.96% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.